You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)以5,000萬美元向施維雅出售「拓舒沃」大中華及新加坡獨家權益
阿思達克 12-21 17:30
基石藥業(02616.HK)宣布與法國制藥企業施維雅達成協議,計劃將產品「拓舒沃」(艾伏尼布片)的大中華地區和新加坡開發、生產和商業化獨家權利,轉讓給施維雅。 根據協議,現金代價最多為5,000萬美元,當中最多600萬美元會在過渡計劃協議完成及業務有序轉讓後支付。交易預期所得款項淨額最高達約4,640萬美元。 由於雙方已訂立新協議,因此原有的許可協議將被終止,公司將無需再支付後續的研發及商業化里程碑付款。基石藥業認為,交易將最大化該產品的價值及影響力,是提升股東及全球患者價值的最好機會,預期可令集團更專注於發展其他管線資產,同時尋求其他機會以進一步拓展其藥物產品的現有管線。 基石藥業與Agios公司於2018年達成獨家合作與授權協議,先後獲得拓舒沃在大中華地區和新加坡的開發和商業化權利,隨後施維雅於2021年收購Agios公司腫瘤業務。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account